Molecular Partners (NASDAQ:MOLN) Rating Increased to Strong-Buy at Leerink Partnrs

Molecular Partners (NASDAQ:MOLN) was upgraded by investment analysts at Leerink Partnrs to a “strong-buy” rating in a research note issued to investors on Monday, Zacks.com reports.

Molecular Partners Price Performance

Shares of MOLN opened at $4.91 on Monday. Molecular Partners has a 1 year low of $3.32 and a 1 year high of $12.70. The stock’s fifty day moving average price is $5.78 and its two-hundred day moving average price is $5.28. The firm has a market cap of $179.97 million, a PE ratio of -2.65 and a beta of 0.99.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.51) earnings per share (EPS) for the quarter. The firm had revenue of $1.72 million during the quarter. Molecular Partners had a negative net margin of 730.27% and a negative return on equity of 33.15%. Sell-side analysts anticipate that Molecular Partners will post -2.03 earnings per share for the current fiscal year.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.